WASHINGTON, Jan 8 (Reuters) - A U.S. regulatory review of the controversial cholesterol drug Vytorin, made by Merck & Co Inc (MRK.N) and Schering-Plough Corp (SGP.N), found the drug works and should still be used, but the positive finding may be too late to win back patients.